Faculty

Javier L. Munoz, M.D., M.B.A.

Clinical Studies

Open

MC230813 Phase 2 Study Of Golcadomide With Rituximab As A Bridging Therapy Prior To CAR-T For Patients With Relapsed Or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Mankato, Minn., Rochester, Minn., Jacksonville, Fla., La Crosse, Wis., Eau Claire, Wis., Scottsdale/Phoenix, Ariz., Albert Lea, Minn.
The purpose of this study is to evaluate efficacy as measured by the disease control rate (CMR, PMR, and NMR) by Lugano 2014 PET-CT based assessment after 2 cycles of therapy.

Contact Us for the Latest Status

An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases Scottsdale/Phoenix, Ariz.
The purpose of this study is to assess the effectiveness and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

Closed for Enrollment

A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamic effects of CTX131 in adult study subjects with relapsed or refractory (r/r) hematologic malignancies.
ALLO-501A-201: A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-501A, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY, AND ALLO-647, AN ANTI-CD52 MONOCLONAL ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) (Alpha-2) Scottsdale/Phoenix, Ariz.
The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) to determine the maximum tolerated dose (MTD).

.

.